Evidence map›Paper›PMID 35947609›Full record

ArticlePloS one2022

Diagnostic performance of the AID line probe assay in the detection of Mycobacterium tuberculosis and drug resistance in Romanian patients with presumed TB.

Andrea Rachow, Elmar Saathoff, Roxana Mindru, Oana Popescu, Doinita Lugoji, Beatrice Mahler, Matthias Merker, Stefan Niemann, Ioana D Olaru, Sabine Kastner and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Andrea RachowDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-4729-3405
Elmar SaathoffDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.
Roxana MindruMarius Nasta Institute of Pulmonology, Bucharest, Romania.
Oana PopescuMarius Nasta Institute of Pulmonology, Bucharest, Romania.
Doinita LugojiMarius Nasta Institute of Pulmonology, Bucharest, Romania.
Beatrice MahlerMarius Nasta Institute of Pulmonology, Bucharest, Romania.
Matthias MerkerDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Stefan NiemannDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Ioana D OlaruDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Sabine KastnerDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.
Michael HoelscherDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.
Christoph LangeDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Elmira IbraimMarius Nasta Institute of Pulmonology, Bucharest, Romania.
Institutul de Pneumoftiziologie "Marius Nasta" · ROLMU Klinikum · DEResearch Center Borstel - Leibniz Lung Center · DEBaylor College of Medicine · USGerman Center for Infection Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe AID line probe assay has shown promising evaluation data on the detection of Mycobacterium tuberculosis as well as 1st- and 2nd-line drug resistance, using isolates and selected clinical samples in previous studies.

methodsThe diagnostic performance of three AID-modules (AID INH/RIF, AID FQ/EMB and AID AG) was analyzed in sputum samples from patients with presumed tuberculosis against culture methods and phenotypic drug resistance as reference standards.

results59 patients had culture-confirmed tuberculosis. All AID modules showed moderate sensitivity (46/59, 78.0%, 65.3-87.7) and very good specificity (100%, 95.5%, 93.7%). There was a high proportion of invalid tests, resulting in 32.6%, 78.3% and 19.6% of 46 AID-positive tuberculosis cases, who could not be assessed for drug resistance by the AID INH/RIF-, AID FQ/EM- and AID AG-module, respectively. A small number of patients showed drug resistance by reference standards: Three MDR-TB cases plus three, one and one patients with resistance to streptomycin, fluoroquinolones and aminoglycosides, respectively. The AID-assay detected all MDR-TB cases, two of three streptomycin-resistant TB cases, one of one of fluoroquinolone-resistant and missed one aminoglycoside-resistant TB case. DISCUSSION: The high proportion of invalid results precludes the use of the AID-assay from direct sputum-based tuberculosis and drug-resistance testing.

Indexed as

Mycobacterium tuberculosisTuberculosis, Lymph NodeTuberculosis, Multidrug-ResistantAntitubercular AgentsDrug ResistanceFluoroquinolonesHumansMicrobial Sensitivity TestsRifampinRomaniaStreptomycinAntitubercular AgentsFluoroquinolonesRifampinStreptomycin

Identifiers

PMID35947609
PMCPMC9365181
OpenAlexW4291675939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.